Cargando…
Adherence to Antipsychotic Medication and Quality of Life in Latin-American Patients Diagnosed with Schizophrenia
PURPOSE: The purpose of this study was to describe the association between adherence to antipsychotic medication and quality of life (QoL) in a sample of individuals diagnosed with schizophrenia. METHODS: Two hundred fifty-three patients were included from three public mental health services from Bo...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7481279/ https://www.ncbi.nlm.nih.gov/pubmed/32943851 http://dx.doi.org/10.2147/PPA.S265312 |
_version_ | 1783580566573023232 |
---|---|
author | Caqueo-Urízar, Alejandra Urzúa, Alfonso Mena-Chamorro, Patricio Fond, Guillaume Boyer, Laurent |
author_facet | Caqueo-Urízar, Alejandra Urzúa, Alfonso Mena-Chamorro, Patricio Fond, Guillaume Boyer, Laurent |
author_sort | Caqueo-Urízar, Alejandra |
collection | PubMed |
description | PURPOSE: The purpose of this study was to describe the association between adherence to antipsychotic medication and quality of life (QoL) in a sample of individuals diagnosed with schizophrenia. METHODS: Two hundred fifty-three patients were included from three public mental health services from Bolivia, Peru, and Chile. Data were collected using the Drug Attitude Inventory (DAI-10) and the Schizophrenia Quality of Life short-version questionnaire (SQoL-18), which considers 8 dimensions. RESULTS: Significant associations were found between adherence to antipsychotic medication treatment and QoL (S-QoL-18 index: β = 0.26, p = 0.004; self-esteem: β = 0.37, p = 0.000; and sentimental life: β = 0.20, p = 0.033). Associations of clinical and socio-demographic variables with QoL were identified: severity of psychotic symptoms, awareness of the disease, gender, age, and ethnicity were found to be associated with a lower level of QoL (β from 0.14 −0.56). CONCLUSION: This study provides evidence of the association between adherence to treatment and quality of life in patients diagnosed with schizophrenia. Therefore, as in developed countries, improving adherence to antipsychotic medication would appear to be an important issue to address to improve patients’ QoL in Latin American countries. |
format | Online Article Text |
id | pubmed-7481279 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-74812792020-09-16 Adherence to Antipsychotic Medication and Quality of Life in Latin-American Patients Diagnosed with Schizophrenia Caqueo-Urízar, Alejandra Urzúa, Alfonso Mena-Chamorro, Patricio Fond, Guillaume Boyer, Laurent Patient Prefer Adherence Original Research PURPOSE: The purpose of this study was to describe the association between adherence to antipsychotic medication and quality of life (QoL) in a sample of individuals diagnosed with schizophrenia. METHODS: Two hundred fifty-three patients were included from three public mental health services from Bolivia, Peru, and Chile. Data were collected using the Drug Attitude Inventory (DAI-10) and the Schizophrenia Quality of Life short-version questionnaire (SQoL-18), which considers 8 dimensions. RESULTS: Significant associations were found between adherence to antipsychotic medication treatment and QoL (S-QoL-18 index: β = 0.26, p = 0.004; self-esteem: β = 0.37, p = 0.000; and sentimental life: β = 0.20, p = 0.033). Associations of clinical and socio-demographic variables with QoL were identified: severity of psychotic symptoms, awareness of the disease, gender, age, and ethnicity were found to be associated with a lower level of QoL (β from 0.14 −0.56). CONCLUSION: This study provides evidence of the association between adherence to treatment and quality of life in patients diagnosed with schizophrenia. Therefore, as in developed countries, improving adherence to antipsychotic medication would appear to be an important issue to address to improve patients’ QoL in Latin American countries. Dove 2020-09-03 /pmc/articles/PMC7481279/ /pubmed/32943851 http://dx.doi.org/10.2147/PPA.S265312 Text en © 2020 Caqueo-Urízar et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Caqueo-Urízar, Alejandra Urzúa, Alfonso Mena-Chamorro, Patricio Fond, Guillaume Boyer, Laurent Adherence to Antipsychotic Medication and Quality of Life in Latin-American Patients Diagnosed with Schizophrenia |
title | Adherence to Antipsychotic Medication and Quality of Life in Latin-American Patients Diagnosed with Schizophrenia |
title_full | Adherence to Antipsychotic Medication and Quality of Life in Latin-American Patients Diagnosed with Schizophrenia |
title_fullStr | Adherence to Antipsychotic Medication and Quality of Life in Latin-American Patients Diagnosed with Schizophrenia |
title_full_unstemmed | Adherence to Antipsychotic Medication and Quality of Life in Latin-American Patients Diagnosed with Schizophrenia |
title_short | Adherence to Antipsychotic Medication and Quality of Life in Latin-American Patients Diagnosed with Schizophrenia |
title_sort | adherence to antipsychotic medication and quality of life in latin-american patients diagnosed with schizophrenia |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7481279/ https://www.ncbi.nlm.nih.gov/pubmed/32943851 http://dx.doi.org/10.2147/PPA.S265312 |
work_keys_str_mv | AT caqueourizaralejandra adherencetoantipsychoticmedicationandqualityoflifeinlatinamericanpatientsdiagnosedwithschizophrenia AT urzuaalfonso adherencetoantipsychoticmedicationandqualityoflifeinlatinamericanpatientsdiagnosedwithschizophrenia AT menachamorropatricio adherencetoantipsychoticmedicationandqualityoflifeinlatinamericanpatientsdiagnosedwithschizophrenia AT fondguillaume adherencetoantipsychoticmedicationandqualityoflifeinlatinamericanpatientsdiagnosedwithschizophrenia AT boyerlaurent adherencetoantipsychoticmedicationandqualityoflifeinlatinamericanpatientsdiagnosedwithschizophrenia |